DDInter1524 DDInter927
A derivative of procaine with less CNS action.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Procainamide {u} (Compound) resembles {v} (Compound) Aminohippurate
Procainamide {u} (Compound) resembles {v} (Compound) Procaine
Procainamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metoclopramide
Procainamide {u} (Compound) binds {v} (Gene) SCN11A
Procainamide {u} (Compound) causes {v} (Side Effect) Vomiting
Procainamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Alosetron
Procainamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Infliximab
Procainamide {u} may lead to a major life threatening interaction when taken with {v} Cladribine
Procainamide {u} may lead to a major life threatening interaction when taken with {v} Ivosidenib
Procainamide {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lidocaine
Procainamide (Compound) resembles Aminohippurate (Compound)
Procainamide (Compound) resembles Procaine (Compound)
Procainamide may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide
Procainamide (Compound) binds SCN11A (Gene)
Procainamide (Compound) causes Vomiting (Side Effect)
Procainamide may cause a minor interaction that can limit clinical effects when taken with Alosetron
Procainamide may cause a moderate interaction that could exacerbate diseases when taken with Infliximab
Procainamide may lead to a major life threatening interaction when taken with Cladribine
Procainamide may lead to a major life threatening interaction when taken with Ivosidenib
Procainamide (Compound) resembles Lidocaine (Compound) and Procainamide may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine